

## Seeking Malignant Pleural Effusion Patients

Diagnosed with late-stage, metastatic breast, ovarian, lung cancers, also primary NSCLC or Mesothelioma

### About RSO-021

Is a novel first-in-class small molecule that irreversibly binds mitochondrial PRX3. This inhibition of the antioxidant signaling network results in selective killing of malignant cells by upregulation of oxidative stress; in contrast, healthy tissue is spared.

**RSO-021  
+ Paclitaxel**

**MPE + Breast, Ovarian, NSCLC**

**RSO-021  
Monotherapy**

**Local Lung Tumor Control**  
**MPE + Other Tumours**

**Newly Diagnosed**  
**MESO WoO**

**Failed Standard of Care**  
**MESO  $\geq$  2L**

Clinicaltrials.gov **REF# NCT05278975**



### MOA

Increased mitochondrial activity and altered redox status are essential for tumor cell growth and metastasis. These cancer specific metabolic adaptations provide a vulnerability exploitable by redox-dependent therapies.

### RSO-021 Localized Therapy

- Allows for direct contact between the drug therapy and the tumour(s).
- This results in an increased concentration of drug in the local environment
- Therapy is delivered through an intrapleural catheter (IPC)

### Multiple NHS Trial Sites

Guy's Hospital® London | St. Bartholomew's Hospital® London | St. James Hospital® Leeds | The Christie® Manchester | Oxford University® | University of Leicester | The Scotland Institute-Glasgow® | Southmead Hospital-Bristol

### For more information



Call: +44 20 8135 8316  
mitope@RSOncology.com  
www.RSOncology/MITOPE